| SOLENO THERAPEUTICS |
| USA |
| Gesundheit |
| US8342033094 / A3DS0P |
| 6XC (Frankfurt) / SLNO (NASDAQ) |
| FRA:6XC, ETR:6XC, 6XC:GR, NASDAQ:SLNO |
| - |
| https://soleno.life/ |
|
Soleno Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for rare diseases. Its primary product, VYKAT XR (diazoxide choline extended-release tablets), is an FDA-approved once-dai..
>Volltext.. |
| 2325.13 Mio. EUR |
| 2109.65 Mio. EUR |
| 162.57 Mio. EUR |
| 14.49 Mio. EUR |
| 17.48 Mio. EUR |
| 0.22 EUR |
| 44.87 Mio. EUR |
| 59.86 Mio. EUR |
| 39.9 Mio. EUR |
| 4.98 |
| - |
| - |
| - |
| - |
| - |
| SOLENO |
| 01.05.26 |